How does luteolin slow diffuse large B-cell lymphoma?
The flavonoid luteolin inhibited DLBCL cell growth (IC50 ~11–12 μM), drove G2/M arrest and apoptosis, and shrank U2932 xenografts while lowering p-JAK2/p-STAT3.
Source
Luteolin inhibits diffuse large B-cell lymphoma cell growth through the JAK2/STAT3 signaling pathway
Study at a glance
- Design
- Animal / in-vitro — DLBCL cell lines (U2932, OCI-LY10) plus U2932 xenograft nude mice (4 groups × n=5) and JAK2 docking/MD.
- N
- N=20 · In vivo n=5 mice × 4 dose groups (0, 12.5, 25, 50 mg/kg); in vitro two human DLBCL lines.
- Population
- Human DLBCL cell lines U2932 and OCI-LY10 and U2932-bearing nude mice.
- Outcome
- Proliferation IC50, apoptosis, G2/M arrest, xenograft growth, and p-JAK2/p-STAT3 vs total JAK2/STAT3.
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
How does luteolin slow diffuse large B-cell lymphoma?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
U2932 IC50 = 10.91 μM at 72 h.
we treated U2932 cells with luteolin for 72 h and determined that it significantly inhibited cell proliferation, with an IC 50 value of 10.91 μM, compared to the control group
OCI-LY10 IC50 = 12.03 μM.
luteolin also markedly reduced the viability of OCI-LY10 cells, with an IC 50 value of 12.03 μM
What they did
CCK-8, Annexin V, and cell-cycle assays on U2932/OCI-LY10 at 0–20 μM; nude mice with U2932 tumors got 12.5/25/50 mg/kg luteolin IP twice daily for 14 days vs saline; Western blots and JAK2 docking/MD.
What they found
IC50 10.91 μM (U2932) and 12.03 μM (OCI-LY10). Apoptosis at 20 μM reached ~54% (U2932) and ~67% (OCI-LY10). G2/M fractions rose dose-dependently. Xenograft volume/weight fell without much body-weight loss; p-JAK2 and p-STAT3 fell while total JAK2/STAT3 stayed flat; Bax/cleaved caspase-3/PARP1 rose.
The limits
What it doesn't show
No human trial; two cell lines and n=5/group mice; JAK2 binding is computational; clinical DLBCL already has R-CHOP, so luteolin is a candidate mechanism, not a proven therapy.
Key terms
- Luteolin
- Dietary/botanical flavonoid tested here as an anti-DLBCL compound.
- DLBCL
- Diffuse large B-cell lymphoma, an aggressive B-cell cancer.
- JAK2/STAT3
- Kinase–transcription-factor path promoting lymphoma survival; luteolin reduced the phosphorylated forms.
- IC50
- Concentration inhibiting 50% of cell growth (~11–12 μM at 72 h).
- G2/M arrest
- Cell-cycle block before mitosis, increased by luteolin in both lines.
Flashcards
0 of 8 answers reviewed
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
U2932 IC50 was about:
Common questions
U2932 IC50?
10.91 μM after 72 h.
Mouse doses?
12.5, 25, and 50 mg/kg IP twice daily for 14 days (n=5/group).
Did total JAK2/STAT3 fall?
No; only phosphorylated JAK2 and STAT3 decreased.
20 μM apoptosis in U2932?
About 53.8%.
More on Oncology outcomes